Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Leavitt

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Annals of the New York Academy of Sciences|March 26, 2011
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentariumBach-Yen T Nguyen, Robin D Isaacs, Hedy Teppler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
The New England Journal of Medicine|December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M Marty, Per Ljungman, Roy F Chemaly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Journal of Virology|December 1, 1996
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorJ H Condra, D J Holder, W A Schleif, et al.
Annals of Internal Medicine|October 7, 2014
Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1J L Lennox, R J Landovitz, H J Ribaudo, et al.
Annals of Internal Medicine|October 7, 2014
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trialJeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Annals of the New York Academy of Sciences|March 26, 2011
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentariumBach-Yen T Nguyen, Robin D Isaacs, Hedy Teppler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
The New England Journal of Medicine|December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M Marty, Per Ljungman, Roy F Chemaly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Journal of Virology|December 1, 1996
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorJ H Condra, D J Holder, W A Schleif, et al.
Annals of Internal Medicine|October 7, 2014
Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1J L Lennox, R J Landovitz, H J Ribaudo, et al.
Annals of Internal Medicine|October 7, 2014
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trialJeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, et al.
Pageof 6